目的 運用Meta分析方法評價腎康注射液治療慢性腎衰竭的療效。方法 通過檢索中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(CBM)、中國期刊全文數(shù)據(jù)庫(CNKI)、中文科技期刊全文數(shù)據(jù)庫(維普)、萬方數(shù)字化期刊全文庫等數(shù)據(jù)庫,對納入的隨機對照試驗文獻(xiàn)進(jìn)行質(zhì)量評價,并采用Rev Man 5.2軟件進(jìn)行Meta分析。結(jié)局指標(biāo)為血尿素氮(BUN)、血肌酐(Scr)和肌酐清除率(Ccr)。結(jié)果 共納入16篇隨機對照試驗,共1 064名患者。Meta分析結(jié)果顯示,腎康注射液能顯著降低BUN[WMD=-3.45,95%CI(-5.72,-1.18),P < 0.01]和Scr[WMD=-0.77,95%CI(-1.16,-0.38),P < 0.01],提高Ccr方面與對照組無統(tǒng)計學(xué)意義[WMD=0.25,95%CI(-0.32,0.83)]。結(jié)論 腎康注射液能顯著降低BUN和Scr,但本研究納入的文獻(xiàn)質(zhì)量較低,期待更多大樣本、高質(zhì)量的隨機對照實驗。

Objective To evaluate the efficacy of Shenkang Injection in treatment of chronic renal failure by Meta analysis. Methods By searching Chinese biomedical literature database (CBM), China Journal Full-text Database (CNKI), Chinese Science and Technology Journal Full-text Database (VIP), and Wanfang Database, etc, the quality assessment of qualified randomly control trials was evaluated. Meta analysis was carried out by Rev Man 5.2 software. The outcomes included blood urea nitrogen (BUN), serum creatinine (Scr), and creatinine clearance rate (Ccr). Results A total of 16 studies were included, involving 1064 patients. Meta analysis showed that ShenKang Injection could significantly decrease in BUN [MD = -3.45, 95%CI (-5.72, -1.18), P < 0.01] and Scr [MD = -0.77, 95%CI (-1.16, -0.38)]. There was no significantly increase in Ccr [MD = 0.25, 95%CI (-0.32, 0.83)]. Conclusion Shenkang Injection can decrease BUN and Scr. But the quality of included studies is low, more high quality of randomized trails are expected.